<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847623</url>
  </required_header>
  <id_info>
    <org_study_id>20149-582</org_study_id>
    <nct_id>NCT03847623</nct_id>
  </id_info>
  <brief_title>Effect of Preoperative Curcumin in Breast Cancer Patients</brief_title>
  <acronym>EPC</acronym>
  <official_title>Effect of Preoperative Curcumin in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of curcumin on modulation of immune and inflammatory parameters in pre-operative
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with breast cancer will be supplemented with either curcumin or placebo
      for a minimum period of 2 weeks and may be extended up to 4 weeks prior to their surgery.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 18, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour infiltrating lymphocytes (TILs)</measure>
    <time_frame>For 2 to 4 weeks</time_frame>
    <description>Scoring as per recommendations by International Immuno-Oncology Biomarker Working Group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FOXP3</measure>
    <time_frame>For 2 to 4 weeks</time_frame>
    <description>Immunohistochemistry analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD68</measure>
    <time_frame>For 2 to 4 weeks</time_frame>
    <description>Immunohistochemistry analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules, taken orally, 8g per day (Bi-daily dosing)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsules, taken orally, bi-daily dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Natural compound, active ingredient of turmeric, in bi-daily dosing</description>
    <arm_group_label>Curcumin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets at bi-daily dosing</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with operable breast cancer

          -  Life expectancy of at least 3 months

          -  Adequate organ function

          -  No allergy to curcumin

          -  Provides consent to participate in trial and adhere to the study protocol

        Exclusion Criteria:

          -  Receiving concomitant radiotherapy, hormonal, immune therapy or other investigational
             drugs

          -  Uncontrolled concurrent illness

          -  Patient of anti platelet medications

          -  Pregnant / breast feeding

          -  Patients who are unable or unwilling to take curcumin, herbal remedies, or
             non-prescription medications

          -  Patients with bleeding tendency, bleeding disorders and abnormal bleeding/clotting
             profile
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nur Aishah Taib, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Malaya Medical Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Nur Aishah Mohd Taib</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

